Identification of Soat1 as a Quantitative Trait Locus Gene on Mouse Chromosome 1 Contributing to Hyperlipidemia by Lu, Zongji et al.
Identification of Soat1 as a Quantitative Trait Locus Gene
on Mouse Chromosome 1 Contributing to
Hyperlipidemia
Zongji Lu
1., Zuobiao Yuan
1., Toru Miyoshi
1, Qian Wang
1, Zhiguang Su
1, Catherine C. Chang
3, Weibin
Shi
1,2*
1Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia, United States of America, 2Department of Biochemistry and Molecular
Genetics, University of Virginia, Charlottesville, Virginia, United States of America, 3Department of Biochemistry, Dartmouth Medical School, Hanover, New Hampshire,
United States of America
Abstract
We previously identified two closely linked quantitative trait loci (QTL) on distal chromosome 1 contributing to major
variations in plasma cholesterol and triglyceride levels in an intercross derived from C57BL/6 (B6) and C3H/HeJ (C3H)
apolipoprotein E-deficient (apoE
2/2) mice. Soat1, encoding sterol o-acyltransferase 1, is a functional candidate gene located
underneath the proximal linkage peak. We sequenced the coding region of Soat1 and identified four single nucleotide
polymorphisms (SNPs) between B6 and C3H mice. Two of the SNPs resulted in amino-acid substitutions (Ile147Val and
His205Tyr). Functional assay revealed an increased enzyme activity of Soat1 in peritoneal macrophages of C3H mice relative
to those of B6 mice despite comparable protein expression levels. Allelic variants of Soat1 were associated with variations in
plasma cholesterol and triglyceride levels in an intercross between B6.apoE
2/2 and C3H.apoE
2/2 mice. Inheritance of the
C3H allele resulted in significantly higher plasma lipid levels than inheritance of the B6 allele. Soat1 variants were also
significantly linked to major variations in plasma esterified cholesterol levels but not with free cholesterol levels. Trangenic
expression of C3H Soat1 in B6.apoE
2/2 mice resulted in elevations of plasma cholesterol and triglyceride levels. These
results indicate that Soat1 is a QTL gene contributing to hyperlipidemia.
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Introduction
Hyperlipidemia, comprising elevated levels of plasma choles-
terol, triglyceride, or both, is a major risk factor for atherosclerotic
cardiovascular disease [1]. Although a small subset of hyperlipi-
demia cases are caused by rare mutants that result in Mendelian
traits segregating in families, the common forms of hyperlipidemia
involve multiple genes and exhibit significant gene-environment
interactions [2]. Recent genome-wide association studies (GWAS)
have been remarkably successful in identifying novel genetic loci
contributing to lipid metabolism [3], although it is challenging
to establish causality between a genetic variant and trait in
humans due to small gene effect, complex genetic structure, and
environmental influences.
One effective approach to the identification of complex trait
genes is the use of mouse models. Apolipoprotein E-deficient
(apoE
2/2) mice develop spontaneous hyperlipidemia and athero-
sclerosis even when fed a low-fat diet [4],[5]. Using intercrosses
derived from apoE
2/2 mouse strains, we and others have
identified distal chromosome 1 as a major region contributing to
hyperlipidemia [6],[7],[8]. QTL analysis of an intercross derived
from C57BL/6 (B6) and C3H/HeJ (C3H) apoE
2/2 mice has
suggested that two closely linked loci in the distal chromosome 1
region account for major variations in plasma HDL, non-HDL
cholesterol, and triglyceride levels [7]. The distal locus corresponds
toHdlq5,a HDL QTLidentifiedinadvanced intercrosslinesderived
from B6 and NZB/B mice [9]. Subsequent studies have identified
Apoa2 as the causative gene of Hdlq5 [10]. The proximal locus
overlaps with Cq1 (158.6 Mbp), a locus identified in a B66KK-Ay
intercross for plasma cholesterol concentrations [11]. Soat1 is a
functional candidate gene close to the linkage peak of the proximal
QTL. It encodes an enzyme in the endoplasmic reticulum that
catalyzes the formation of cholesteryl esters from cholesterol and
fatty acyl coenzyme A [12]. In mammals, two Soat genes have been
identified: Soat1 is ubiquitously expressed and is responsible for
cholesteryl ester formation in the brain, adrenal glands, macrophag-
es, kidneys, and the liver, and Soat2 is expressed in the liver and
intestines. Soat1 deficiency results in a significant reduction in non-
HDL levels of apoE
2/2 and LDLR
2/2 mice fed a chow or Western
diet [13]. Human genetic studies indicate that Soat1 variants are
associated with elevations in plasma concentrations of HDL
cholesterol and apoA-I among subjects with hyperlipidemia [14].
In the present study, we tested whether Soat1 was a QTL gene
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25344contributing to naturally occurring variation in plasma lipid levels,
especially under the circumstances of hyperlipidemia, in mice.
Results
Soat1 sequence variation
As part of an effort to find causal genes for the proximal lipid
QTL on distal chromosome 1, all genes within the confidence
interval(154.9,172.8 Mb)wereperused forsequencedifferencesin
coding or promoter regions between B6 and C3H mice by querying
public accessible databases (http://www.ncbi.nlm.nih.gov/SNP/
MouseSNP.cgi, http://cgd.jax.org/tools/diversityarray.shtml, and
www.ensembl.org). 16 likely candidate genes whose sequence
variations may lead to changes in either the structure or quantity
of a gene product were identified, which included Qsox1, Cep350,
Tor1aip1, Tdrd5, Nphs2, Soat1, Tor3a, sec16b, Lztr2, Tnr, AI848100,
LOC100040571, 1700015E13Rik, Nos1ap, Olfml2b, and Atf6. Among
them, Soat1 is a gene located close to the linkage peak and is also
involved in lipid metabolism. We sequenced the coding region of
Soat1 by using cDNA as template and found four SNPs between B6
and C3H mice (Figure 1) (the accession number of the C3H/HeJ
Soat1 gene sequence in the NCBI GenBank is bankit838062
DQ903181). Two SNPs, A/G at position 439 and C/T at 613, led
to amino-acid substitutions with isoleucine (Ile) to valine (Val) at
amino acid residue 147 (Ile147Val) and histidine (His) to tyrosine
(Tyr) at residue 205 (His205Tyr), respectively. The other two SNPs,
A/C at 421 and C/T at 454, were synonymous base changes.
We compared Soat1 peptide sequences of five mammal species,
including the mouse, and found that 205His is conserved in
humans,chimpanzees,dogs,rats,and B6mice(Figure2),suggesting
that 205Tyr is a mutation in C3H mice. The nonsynonymous SNP
at 439 also represents a conservative change from leucine to
isoleucine in B6 or to valine in C3H.
Enhanced enzyme activity
Soat1 activity was determined in vitro using cell homogenates
prepared from peritoneal macrophages of B6.apoE
2/2 and
C3H.apoE
2/2 mice. The enzyme activity was optimally solubi-
lized with the zwitterionic detergent CHAPS at concentrations of
1–3% (Figure 3A). At all the concentrations used, the Soat
specificity activity was nearly twice as high in C3H as in B6
(P,0.05). The expression of Soat1 in peritoneal macrophages was
examined by western blot analysis (Figure 3B). Densitometry of
Soat1 bands was comparable between the two strains [442660 vs.
4216115 (optical density); P=0.87].
Association with variation in plasma lipid levels
We then examined whether Soat1 variants were associated with
variations in plasma HDL, non-HDL cholesterol, and triglyceride
levels in female F2 mice derived from B6.apoE
2/2 and
C3H.apoE
2/2 mice. As shown in Table 1, inheritance of two
copies of the C3H allele (CC genotype) resulted in significantly
higher triglyceride, HDL, and non-HDL cholesterol levels than
inheritance of two copies of the B6 allele (BB genotype) at the Soat1
locus (P,0.05 for each trait).
Linkage to plasma esterified cholesterol
Because Soat1 is an enzyme that catalyzes free cholesterol to
cholesterol esters, we determined whether the Soat1 locus was
linked to variations in plasma esterified and free cholesterol levels
in the BXH cross. QTL analysis of F2 mice revealed that loci on
chromosome 1 were responsible for major variations in plasma
esterified cholesterol and free cholesterol levels (Figure 4). The
interval mapping graph for chromosome 1 showed that the
proximal peak of linkage curves for esterified cholesterol
overlapped precisely with the Soat1 locus (Figure 5), which had a
LOD score of 4.2 and explained 8% of the variance (Table 2). The
distal peak of linkage curves appeared near marker D1Mit206
(174.9 Mbp), which had a LOD score of 4.4 and accounted for
9% of the variance. In contrast, free cholesterol was controlled by
two significant QTLs on chromosome 1, near markers D1Mit45
(94.9 Mbp) and D1Mit270 (172.7 Mbp), respectively, and a
suggestive locus near marker D9Mit297 (33.8 Mbp) on chromo-
some 9. The QTL near marker D1Mit45 had a significant LOD
Figure 1. Selected sequence traces of Soat1 cDNA of B6 and C3H mice. Differences between the two strains in nucleotides or amino acid
residues are highlighted. Partial sequences of Soat1 cDNA are not presented because no sequence difference has been found between the two
strains.
doi:10.1371/journal.pone.0025344.g001
Soat1 and Hyperlipidemia
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e25344score of 4.6 and accounted for 9% of the variance, and the QTL
near marker D1Mit270 had a LOD score of 3.4 and explained 7%
of the variance. The suggestive QTL near marker D9Mit297
(33.9 Mbp) for free cholesterol had a LOD score of 3.3 and
accounted for 6% of the variance, and this QTL overlaps with Cq4
and Cq5 mapped in B66KK-A F2 and KK6RR F2 crosses [11].
Analysis of transgenic mice
To directly evaluate the role of Soat1 in hyperlipidemia, we
constructed transgenic mice that expressed C3H Soat1 and crossed
the mice with B6.apoE
2/2 mice for more than six generations.
The expression of Soat1 protein in transgenic mice was analyzed by
western blotting, and it was found in the liver, kidney, spleen, and
the lung but not in the aorta, heart, or skeletal muscle (Figure 6).
Real-time PCR analysis revealed that Soat1 mRNA expression
levels in the liver were 2-fold as high in transgenic mice as in non-
transgenic littermates (6.5761.04 vs. 3.4760.44 per 10,000 copies
of GAPDH; P=0.029). The mRNA expression level of GAPDH
was comparable between transgenic and non-transgenic mice with
respect to real-time PCR cycle threshold values (18.1760.32 vs.
18.3160.28). Soat1 protein in the liver was higher in transgenic
mice than non-transgenic littermates (optical density:
617526261338918 vs. 427065461017286), although the differ-
ence was not statistically significant (P=0.295). Compared to non-
transgenic littermates, transgenic mice had significantly elevated
plasma levels of non-HDL cholesterol (308.6618.5 vs.
250.668.4 mg/dl; P=0.029) and HDL cholesterol (68.966.1 vs.
37.262.3 mg/dl; P=0.0048) (Figure 7). Plasma triglyceride levels
were also higher in transgenic mice (78.165.1 vs. 67.065.5 mg/
dl), although the difference was not statistically significant
(P=0.17).
Discussion
QTLs for plasma HDL on mouse distal chromosome 1 have
been reported many times in numerous crosses [15]. QTLs for
plasma triglyceride and non-HDL on distal chromosome 1 have
also been reported in several crosses, including three BXH crosses
[6],[7],[8],[16]. In the intercross between B6.apoE
2/2 and
C3H.apoE
2/2 mice, we have observed that QTLs for HDL
coincide with QTLs for triglyceride and non-HDL on distal
chromosome 1 [7], suggesting that these plasma lipid phenotypes
are controlled by the same genes. We have also observed two
distinct peaks of the linkage curves for plasma triglyceride or non-
HDL with the distal peak near marker D1Mit270 (172.7 Mbp) and
the proximal peak near marker D1Mit425 (158.6 Mbp) [7],
suggesting the existence of two QTLs for plasma lipids in the
distal chromosome 1 region. Two other studies have also suggested
the existence of a lipid QTL near 81.6 cM on mouse chromosome
1 [8], [11].
The distal QTL overlaps with Hdlq5 [9], and there is conclusive
Figure 2. Comparison of Soat1 protein sequences in five mammal species. Amino acid residues that are different between B6 and C3H mice
are highlighted. GenBank accession No. are shown following the names of the species.
doi:10.1371/journal.pone.0025344.g002
Figure 3. Comparison of Soat1 enzyme activity in peritoneal
macrophages harvested from B6.apoE
2/2 and C3H.apoE
2/2
mice (A). Cell homogenates were prepared from five individual mice of
each strain and kept at concentrations of 2–4 mg/ml in a buffer (50 mM
Tris, 1 mM EDTA at pH 7.8 with protease inhibitors). To solubilize the
enzyme, 1 M KCl and various concentrations of CHAPS were added. The
enzyme was assayed in duplicate in taurochoate/cholesterol/PC mixed
micelles. *P,0.05. C3H had significantly higher Soat1 activity levels than
B6. Western blot analysis of Soat1 expression in peritoneal macrophag-
es derived from B6.apoE
2/2 and C3H.apoE
2/2 mice (B). Each lane
represents an individual mouse. There was no significant difference in
Soat1 expression between the two strains.
doi:10.1371/journal.pone.0025344.g003
Table 1. Statistical association between allelic variation at the
Soat1 locus and plasma lipid levels in F2 mice derived from
B6.apoE
2/2 and C3H.apoE
2/2 mice.
Trait BB (n=61) BC (n=112) CC (n=45) Variance (%) P value
Triglyceride 154637 175644 185652 5 2.1610
23
Non-HDL 7016187 8036201 9116262 10 1.0610
25
HDL 26620 38630 38627 3 3.5610
22
Measurements are presented as means 6 SD. The unit for these measurements
is mg/dl. Variance (%) accounted for by the Soat1 locus is expressed as the
percentage of the total phenotypic variance detected in the F2 cohort. BB,
homozygous for C57BL/6 alleles; CC, homozygous for C3H alleles; BC,
heterozygous for C57BL/6 and C3H alleles. The percentage of variance
explained by Soat1 genotype and likelihood ratio P values are shown.
doi:10.1371/journal.pone.0025344.t001
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QTL. Indeed, sequence analysis of the Apoa2 coding region in
many mouse strains has revealed a number of nucleotide
differences [10], [17]. Apoa2 variants are associated with variation
in HDL cholesterol levels of mice [10],[18]. Transgenic overex-
pression of Apoa2 elevates plasma HDL, non-HDL cholesterol, and
triglyceride levels [19], and Apoa2 deficiency reduces plasma HDL,
non-HDL, and triglyceride levels in mice [20].
The present study strongly suggests that Soat1 is the causal gene
for the proximal QTL. Multiple polymorphisms have been found
in the coding region of this gene between the two parental strains
that had been used in our previous studies to map the lipid QTL,
and two of the polymorphisms lead to amino acid substitutions in
the protein product. These polymorphisms led to changes in the
function of Soat1 enzyme. As macrophages express only Soat1,w e
measured its activity in these cells. The present finding that C3H
Figure 4. Genome-wide analyses for main effect loci affecting plasma esterified cholesterol and free cholesterol of female F2 mice
between B6.apoE
2/2 and C3H.apoE
2/2 mice using the R/qtl program. Female F2 mice were fed the western diet for 12 weeks and typed for
genetic markers spanning the genome and for the phenotypes. Chromosomes 1 through X are represented numerically on the X-axis. The relative
width of the space allotted for each chromosome reflects the relative length of each chromosome. The Y-axis represents the LOD score.
doi:10.1371/journal.pone.0025344.g004
Figure 5. LOD score plots for esterified and free cholesterol levels on chromosome 1. The x-axis depicts the marker positions in
centimorgans, and the y-axis depicts the LOD score. The microsatellite markers typed are listed below the x-axis, corresponding to their map
locations on the chromosome.
doi:10.1371/journal.pone.0025344.g005
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comparable protein expression in macrophages indicates that
these SNPs have resulted in increases in Soat activity. This study
has also provided several lines of other evidence supporting Soat1
to be a QTL gene affecting plasma lipid levels. First, the parental
strain C3H, which has higher Soat1 enzyme activity, exhibits
higher plasma cholesterol and triglyceride levels than the B6
strain, which has lower enzyme activity [21]. Second, F2 mice with
the C3H allele at the Soat1 locus had higher plasma cholesterol
and triglyceride levels than those with the B6 allele. Third, the
QTL for esterified cholesterol coincided with the QTLs for
triglyceride, HDL, and non-HDL at the Soat1 locus, suggesting
that a gene involved in cholesterol esterification affected plasma
HDL and non-HDL cholesterol levels. Soat1 is such a gene that
synthesizes cholesterol esters and potentially affects lipoprotein
assembling. Finally, the direct evidence is that transgenic mice
expressing C3H Soat1 had significantly elevated plasma levels of
HDL and non-HDL cholesterol.
A previous study also showed that Soat1 deficiency reduces
plasma total cholesterol levels of apoE
2/2 mice [13]. However,
the previous knockout mice were generated using embryonic stem
cells derived from 129/SvJ mice and then backcrossed onto the B6
background. Linkage would cause the retention of a significant
segment of 129/SvJ chromosome harboring the targeted gene in
recipient mice. Several genes adjacent to Soat1, including Apoa2,
are polymorphic between B6 and 129/SvJ and could contribute to
variations in plasma lipid levels. The present study of transgenic
mice has excluded a possible interference from Apoa2 and thus
provided more definite evidence on the role of Soat1 in modifying
plasma lipid levels. In this study, we found that transgenic mice
had an increased level of HDL cholesterol. In contrast, the effect of
Soat1 on plasma HDL cholesterol was not observed in the
knockout mice. An explanation for the discrepant results is that
apoE
2/2 mice have an extremely low HDL cholesterol level, and
thus it would be harder for a gene to exert an effect to further
reduce than to elevate it. In humans, a missense variant (R526G)
and a variant in the 59 untranslated region (277G.A) have been
found in the Soat1 gene, and individuals with 277G.A variant
have significantly higher plasma HDL concentrations than those
without the variant among hyperlipidemic subjects [14]. Never-
theless, genome-wide association studies (GWAS) to date have
failed to detect any association with lipid traits in humans. One
probable explanation for this outcome is that the gene is large
(64.89 kb) and includes many variants (794 SNPs in the NCBI
dbSNP database). Only a small number of markers in Soat1 have
been typed, and these markers may not have the strongest
association.
Table 2. Significant and suggestive QTL for plasma esterified and free cholesterol in F2 mice derived from B6.apoE
2/2 and
C3H.apoE
2/2 mice.
Chromosome marker (cM)
a Trait LOD
b SI (cM)
c Variance (%)
d Pemp
e Model of inheritance
f
Soat1 (81.6) Esterified cholesterol 4.2 75–89 8 0.002 Additive
D1mit206(95.8) Esterified cholesterol 4.4 87–102 9 0.001 Additive
D1mit45(58.5) Free cholesterol 4.6 41–62 9 0.004 Additive
D1mit270(92.3) Free cholesterol 3.4 73–101 7 0.005 Additive
D9mit297(15) Free cholesterol 3.3 0–27 6 0.008 Additive
aFrom Mouse Genome Informatics database at http://www.informatics.jax.org.
bSuggestive QTL and significant QTL were 2.4 and 3.4, respectively, for free cholesterol and 2.4 and 3.3, respectively, for esterified cholesterol as defined by 1000
permutation tests.
cSupport intervals (SI) were defined by a 1-unit decrease in LOD score on either side of the peak marker.
dVariance (%) indicates the percentage of the phenotypic variance at the peak marker.
ePemp, empirically determined P-value for the whole genome, was calculated using the permutation test function of MapManager QTXb20.
fModel of inheritance was determined using the MapManager QT program. C3H was the high allele at all the markers, contributing to elevated free or esterified
cholesterol levels.
doi:10.1371/journal.pone.0025344.t002
Figure 6. Characterization of Soat1 transgenic mice. A, expres-
sion of Soat1 protein in transgenic mice. PC, positive control: lane
loaded with Soat1 protein; NC, negative control: lane loaded with buffer
only. B, real-time PCR analysis of Soat1 mRNA expression in the liver of
transgenic and non-transgenic (control) littermates. The expression
level of Soat1 was expressed as copy number relative to 10,000 copies
of GAPDH mRNA. Results are means 6 SE of 6 and 5 transgenic and
non-transgenic mice, respectively. C, expression of Soat1 protein in the
liver of transgenic and non-transgenic littermates. Each lane represents
an individual mouse.
doi:10.1371/journal.pone.0025344.g006
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Soat1 to be a QTL gene, although further studies are needed to
prove which SNP affects Soat1 function. Soat enzyme catalyzes
the formation of cholesteryl esters from free cholesterol and fatty
acyl coenzyme A. Because of its potential role in foam cell
formation, this enzyme has been a target for developing
therapeutic drugs for the past two decades. Theoretically,
inhibition of the enzyme should block the esterification of
cholesterol and prevents the transformation of macrophages into
foam cells. However, some animal studies show that Soat
inhibitors exert hypolipidemic effects and reduce atherosclerosis
[22],[23],[24] while some studies show that inhibition of Soat
activity promotes atherosclerosis [25]. In humans, administration
of Soat inhibitors failed to reduce, rather increase, plaque volume
[26],[27]. Studies with more specific inhibitors of Soat1 activity
have also shown aggravation rather than alleviation of atheroscle-
rosis in rabbits and mice [25],[28]. As Soat1 elevates plasma levels
of both good (HDL) and bad (non-HDL) cholesterol, the present
results may explain why Soat1 inhibitors are not clinically effective
as expected and many have failed in clinical stages probably due to
its effect on HDL cholesterol. Moreover, continued inhibition of
Soat activity increases intracellular free cholesterol and limits the
efflux of free cholesterol, which may induce cytotoxic effects within
cells.
Materials and Methods
Ethics statement
All procedures were carried out in accordance with current
National Institutes of Health guidelines and approved by the
University of Virginia Animal Care and Use Committee
(Assurance #A3245-01, Animal Protocol #3109).
Mice
B6.apoE
2/2 mice were purchased from the Jackson Laborato-
ry, and C3H.apoE
2/2 mice were generated in our laboratory.
The generation of F2 mice from B6.apoE
2/2 and C3H.apoE
2/2
mice was reported previously [7]. At 6 weeks of age, female F2
mice were started on a Western-type diet containing 21% but-
terfat, 34% sucrose, and 0.2% cholesterol (TD 88137, Harlan
Laboratories) and maintained on the diet for 12 weeks. To
generate transgenic mice, a clone containing the Soat1 gene in the
pTARBAC2.1 vector was picked from the CHORI-34 Mouse
C3H/HeJ BAC library constructed by the Pieter De Jong’s
Laboratory at Children’s Hospital Oakland Research Institute.
This clone contained the entire Soat1 gene, 142,565 bp upstream
and 14,893 bp downstream from the 59 and 39 ends, respectively.
The integrity of Soat1 was confirmed through partial sequencing
and restriction enzyme digestion before the purified BAC DNA
was microinjected into B6D2 F1 fertilized eggs at a concentra-
tion of 1 mg/ml. Transgenic founders were identified by PCR
amplifications of both forward and reverse fragments of the BAC
DNA with primers 59-TCTTTCTCCGCACCCGACATAGAT-
39/59-TTAGGAGCCACTGTGGTTAGCTGT-39 and 59-
AAGTCAGAACTGTGGCTTGT-39/59-CAGCACTGGTTT-
AAT GTCC-39. Positive transgenic mice were backcrossed with
B6.apoE
2/2 mice for more than 6 generations and maintained in
a heterozygous condition for the transgene.
Plasma lipid measurements
Plasma total cholesterol, HDL cholesterol, and triglyceride were
measured as reported previously [29]. Non-HDL cholesterol was
calculated by subtracting the HDL cholesterol levels from the
total. Free cholesterol levels were determined using a kit from
Wako (Richmond, VA). Briefly, 6 ml of plasma samples, lipid
standards, and controls were loaded in a 96-well plate and then
mixed with 150 ml of free cholesterol reagent. After a 5-min
incubation at 37uC, the absorbance at 600 nm was read on a
Molecular Devices (Menlo Park, CA) plate reader. Esterified
cholesterol levels were calculated by subtracting free cholesterol
levels from total cholesterol levels.
Soat1 cDNA sequencing and genotyping
Total RNA isolated from the liver of B6 mice and C3H mice
was reverse transcribed to cDNA with use of the Superscript RT-
PCR kit (Invitrogen). The PCR primers used for amplification of
Figure 7. Plasma lipid levels of female transgenic and non-transgenic (control) littermates on the B6.apoE
2/2 background. Blood was
collected from overnight fasted mice fed a chow diet. Values are mean 6 SE of 5 transgenic and 8 non-transgenic mice. * P,0.05 vs. non-transgenic
littermates.
doi:10.1371/journal.pone.0025344.g007
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GATTGATAGTGG-39/59-CTTGGGTAGTTGTCTCGGTAA-
39;5 9-GCAAAGATCCACTACCCACAG-39/59-AACACGTA-
CCGACAAGTCCAG-39. After purification with a QIAquick
PCR purification kit, PCR products were sequenced on an ABI
Prism Cycle sequencer 310 (Applied Biosystems). The Soat1
polymorphism at T454C was used to screen the BXH intercross
with the PCR-restriction fragment length polymorphism (PCR-
RFLP)-based method. PCR amplification on genomic DNA was
performed using primers 59-AGATTGTCCCTCTAAGGCGC-
CAA-39 and 59-AGCCTAGCTGGACCACTTTCTCAA-39, and
the 712 bp amplicon was then digested with ClaI restriction
enzyme (New England BioLabs, Hertfordshire, UK) according to
the manufacturer’s instruction. The PCR product from the B6
allele but not that from the C3H allele was digested by ClaIt o
511 bp and 201 bp fragments. Thus, the BB allele should exhibit
two bands, the CC allele one band, and the BC alleles three bands
on an agarose gel.
Soat1 activity assay in macrophages
Peritoneal macrophages were prepared as we previously
described [30]. Following a brief culture as a monolayer in RPMI
medium containing 10% fetal bovine serum, macrophages were
harvested by hypotonic shock and scraping, and the resultant cell
homogenate was kept in a buffer (50 mM Tris, 1 mM EDTA at
pH 7.8 with protease inhibitors) at concentrations of 2–4 mg/ml.
To solubilize the enzyme, 1 M KCl and various concentrations of
CHAPS were added. The enzyme activity of Soat1 was measured
in duplicate in taurochoate/cholesterol/PC mixed micelles as
described by Chang et al [31].
Western blot analysis
The presence of Soat1 in various tissues of transgenic mice and
in peritoneal macrophages of B6.apoE
2/2 and C3H.apoE
2/2
mice was determined by western blot analysis. Proteins were
prepared as we previously described [32], separated by electro-
phoresis on 4–12% Tris-polyacrylamide gels, and electrophoret-
ically transferred to nitrocellulose membranes. The membrane was
probed with a rabbit polyclonal antibody against Soat1 (H-125,
Santa Cruz), and signals were detected by the chemiluminescence
method (Invitrogen). The density of the bands was quantified with
a densitometer (Molecular Devices, CA).
Real-time PCR analysis of Soat1 expression
Total RNA extracted from the liver of transgenic mice was
treated with DNase I, and then reverse transcribed to cDNA as
described above. cDNA was mixed with SYBR Green supermix
reagent (Bio-Rad) and specific primers to assess expression of Soat1
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by
real-time PCR. Primers used for Soat1 amplification were 59-
TGTGCATCAGAAAGGTACCACGGA-39/59-GTTGCCAGGA-
AACCACCAAAGTGA-39 and for GAPDH were 59-GGTGT-
GAACGGA TTTGGCCGTATT-39/59-GGCCTTGACTGTGC-
CGTTGAATTT-39. Real-time PCR on each sample was run in
triplicate on an iCycler iQ5 machine (Bio-Rad) under the condition of
50uCf o r2m i n u t e s ,9 5 uCf o r2m i n u t e s ,t h e n9 5 uC3 0s e c o n d s ,6 0 uC
30 seconds, and 72uC3 0s e c o n d sf o r4 0c y c l e sa sr e p o r t e d[ 3 3 ] .T h e
expression level of Soat1 w a se x p r e s s e da sm R N Ac o p yn u m b e rr e l a t i v e
to 10,000 copies of GAPDH mRNA.
Statistical analysis
QTL analysis was performed as we previously described
[7],[33] ANOVA was used for determining if the mean phenotype
values of progeny with different genotypes at a specific marker
were significantly different. The Student t test was used when only
two means were compared. Differences were considered statisti-
cally significant at P,0.05.
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